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MicroRNA-210-3p is the most prominent hypoxia regulated microRNA, and it has been found significantly 
overexpressed in different human cancers. We performed the expression analysis of miR-210-3p in 
a retrospective cohort of breast cancer patients with a median follow-up of 76 months (n = 283). An 
association between higher levels of miR-210-3p and risk of disease progression (HR: 2.13, 95%CI: 1.33-
3.39, P = 0.002) was found in the subgroup of patients treated with Epirubicin and Cyclophosphamide 
followed by Docetaxel. Moreover, a cut off value of 20.966 established by ROC curve analyses allowed 
to discriminate patients who developed distant metastases with an accuracy of 85% at 3- (AUC: 0.870, 
95%CI: 0.690-1.000) and 83% at 5-years follow up (AUC: 0.832, 95%CI: 0.656–1.000). Whereas the 
accuracy in discriminating patients who died for the disease was of 79.6% at both 5- (AUC: 0.804, 95%CI: 
0.517–1.000) and 10-years (AUC: 0.804. 95%CI: 0.517–1.000) follow-up. In silico analysis of miR-210-3p 
and Docetaxel targets provided evidence for a putative molecular cross-talk involving microtubule 
regulation, drug efflux metabolism and oxidative stress response. Overall, our data point to the miR-
210-3p involvement in the response to therapeutic regimens including Docetaxel in sequential therapy 
with anthracyclines, suggesting it may represent a predictive biomarker in breast cancer patients.
Breast cancer (BC) is the most frequent malignancy that develops in women worldwide and accounts for the 
highest rates of cancer-associated death. Indeed, despite the reported decline of breast cancer mortality in the 
last 15 years1, as a result of screening programs, better education, and implementation of more effective adjuvant 
treatments, about 25–40% of breast cancer patients develops metastases and eventually dies from the disease2. 
These data indicate that currently available prognostic and predictive methods are inadequate to determine pre-
cisely the aggressiveness of the disease and the likelihood of response to a certain treatment in individual patients.
microRNAs (miRNAs, miRs) are short (18–25 nucleotides), highly conserved non-coding RNAs that 
fine-tune gene expression by operating translation inhibition or degradation of protein coding mRNAs via 
imperfect base-pairing to complementary sites on target mRNAs. Soon after their discovery, microRNAs have 
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been attracting much attention due to their frequent dysregulation in human cancers and, more importantly, 
their association with the clinicopathological parameters, the latter supporting their emergence as a new class of 
molecular biomarkers. In this regard, several miRNA profiles of breast cancer have been established by microar-
ray or next-generation sequencing (NGS), and the resulting miRNA signatures have been correlated to the typical 
clinicopathological and prognostic characteristics including tumor size, lymph-node invasion, receptors status, 
and resistance to chemotherapy3–6.
Among these studies, a number of experimental evidences support the clinical relevance for miR-210. miR-
210 is the most prominent hypoxia regulated microRNAs and a direct target of the hypoxia inducible factor 1 
alpha (HIF-1α). Of the two mature forms, namely miR-210-3p and miR-210-5p, miR-210-3p appears to be the 
guide strand functionally involved in a variety of biological processes such as cell cycle, cell survival, stem cell dif-
ferentiation, angiogenesis, DNA damage repair, mitochondrial metabolism, and immune response7–9. Moreover, 
as hypoxia is an important feature of solid tumors, the role of miR-210-3p has been extensively studied in the 
context of cancer progression, where it was shown that miR-210-3p is overexpressed in several malignancies 
including breast, glioblastoma, lung, pancreatic, or head and neck cancer10–15.
In breast cancer, the overexpression of miR-210-3p was initially correlated with a poor prognosis, being asso-
ciated with invasiveness and shorter time to develop distant metastases5,6,10,16–18. In particular, miR-210-3p was 
shown to be up-regulated in triple-negative breast cancer (TNBC) compared to estrogen positive tumors5,18, 
showing relevance even in this group where high levels of miR-210 were found correlating with a higher risk of 
recurrence under tamoxifen treatment19. Interestingly, recent findings by Bar I. et al.20 demonstrated miR-210 
tends to localize and be expressed both in epithelial cancer cells and in the tumor microenvironment (TME) of 
TNBC samples, particularly in inflammatory cells where it is likely to be regulated by a mechanism independent 
of HIF-1α20. In spite of these data, some discrepancies about miR-210-3p significance from a clinical standpoint 
do exist. For instance, by performing the expression profile of nine miRNAs in TNBC, Radojicic et al.21 recently 
reported that there was not a significant association between high expression levels of miR-210-3p and poor 
patient disease free survival and overall survival. Similar findings were reported by Makou A. et al.22 who found a 
significant association between miR-210-3p overexpression and shorter OS only in the ER-positive/HER2- neg-
ative breast cancer subtype.
These discrepancies spurred us to perform a miR-210-3p expression analysis in our large cohort of breast 
cancer patients with a long-term follow-up in the attempt to clarify the correlation of miR-210-3p with clinical 
parameters and help understand if miR-210-3p holds promise as biomarker in breast cancer.
Results
miR-210-3p is overexpressed in tumour samples as compared with normal breast tissues from 
reductive mammoplasty. The expression of miR-210-3p (hsa-miR-210-3p/RNU48x1000) was evaluated 
in 283 breast cancers (see Supplemental Table 1 for clinic-pathological data) and in the normal breast tissues 
obtained from 13 reductive mammoplasties (i.e. glandular tissue, NBTs). It emerged that miR-210-3p was sig-
nificantly up regulated in tumours (Median 10.18; IQR 4.87-19.41) as compared with NBTs (Median 4.64; IQR 
2.71–8.21) (P = 0.021) (data not shown).
miR-210-3p up-regulation is more frequent in triple negative breast cancer. Then, we investi-
gated the association between miR-210-3p expression and tumour clinicopathological characteristics. Higher 
levels of miR-210-3p expression were found in ER negative breast cancers (median 12.9, IQR 5.14–32.95) as 
compared with ER positive tumours (median 9.62; IQR 4.86–18.09) (P = 0.038).
When we compared cancer cases classified on the basis of surrogate molecular classification (Luminal A, 
Luminal B, HER2-amplified and Triple Negative), the Triple Negative subgroup showed the highest level of miR-
210 expression (median 18.31 IQR 7.2–38.61), followed by Luminal B tumours (median 10.57 IQR 5.01–19.41), 
whereas Luminal A (median 8.6; IQR 4.2–15.09), and HER2-amplified tumours (median 8.57 IQR 4.66–24.69) 
showed the lowest expression levels (P = 0.0137). In detail, when pairwise comparisons were performed, we 
found a statistically significant difference between Luminal A vs. Triple Negative subgroup (Bonferroni-adjusted 
P = 0.0133) and also between Luminal B vs. Triple Negative (Bonferroni-adjusted P = 0.0181), respectively 
(Supplemental Table 2).
Evaluation of miR-210–3p prognostic value in breast cancer cases. The association of miR-
210-3p expression with time-to-event outcomes was evaluated in the group of patients without metasta-
ses at diagnosis (M0). Overall Survival (OS) and Progression Free Survival (PFS) data were available for 265 
patients (Supplemental Tables S2, S3), whereas Metastases Free Survival (MFS) data were available for 263 
patients (Supplemental Table S4). Tumour dimension, stage, lymph node status, hormone receptor status, 
HER2-amplification, and surrogate molecular classification were associated with PFS, MFS and OS. Instead, 
Ki67 overexpression was associated with PFS and MFS only. No statistically significant associations were found 
between miR-210-3p and outcomes in univariable analyses as well as in a multivariable model including clinical 
biomarkers indicated in the 8th edition of the American Joint CC Breast Cancer prognostic classification23, which 
includes Pathological Stage (T = Tumour dimension, N = Lymph node status), Grade, HER2, ER and PgR status 
(Supplemental Table S5).
Next, we evaluated the association of miR-210-3p and patient’s outcome in the subgroup identified by adju-
vant treatment (Supplemental Table S6). As shown in Table 1, miR-210-3p expression was associated in both 
univariable and multivariable analyses with an increased risk of disease progression and metastases develop-
ment in the patient’s subgroup treated with the Epirubicin-Cyclofosfamide and Docetaxel (EC + D) scheme. No 
significant association was found within the Fluorouracil (5FU), Epirubicin and Cyclophosphamide (FEC) and 
Epirubicin-Cyclofosfamide (EC) schemes as well as no association was found in the group identified by endocrine 
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and anti-HER2 therapies suggesting that miR-210-3p expression may affect the sensitivity of tumours treated 
with Docetaxel.
High miR-210-3p expression can predict early metastases development and death in patients 
treated with epirubicin-cyclofosfamide and docetaxel (EC + D) regimen. Based on the results 
obtained with survival analyses, we evaluated the discriminatory power of miR-210-3p expression analysis in 
identifying patients who experienced a time-to-event outcome. Again, the highest discriminatory power of miR-
210-3p expression was achieved in the subgroup of patients treated with EC + D. Indeed, the prognostic ability of 
the miR-210-3p expression in discriminating patients who developed distant metastases reached significant AUC 
values of 0.87 (p < 0.001), 0.83 (p = 0.001) and 0.75 (p = 0.010) at 3, 5 and 10 years, respectively. On the basis of 
the ROC curve, the cut-off of 20.966 for miR-210 expression achieved the highest overall accuracies of 85.2% 
(sensitivity: 87.5%, specificity: 84.8%), 83.3% (sensitivity: 77.8%, specificity: 84.4%) and 81.1% (sensitivity: 70.0%, 
specificity: 83.7%) at 3, 5 and 10 years, respectively (Fig. 1C).
Moreover, the same cut off was also accurate in the discrimination of patients who died for the disease, with 
an overall accuracy of 79.6% (sensitivity 80%; specificity of 79.6%) and all miR-210-3p expression values achieved 
an AUC of 0.804 (p = 0.024) at both 5 and 10 years (Fig. 1A). Lastly, the prognostic ability of the miR-210-3p 
expression in identifying patients who developed a disease progression reached significant AUC values of 0.76 
(p = 0.018) and 0.77 (p = 0.010) at 3 and 5 years, respectively. Again, the cut-off of 20.966 achieved the highest 
overall accuracy of 81.5% (sensitivity: 75.0%, specificity: 82.6%) at 3 years whereas the cut-off of 19.764 achieved 
the highest overall accuracy of 81.5% (sensitivity: 77.8%, specificity: 82.2%) at 5 years, respectively (Fig. 1B).
Finally, we evaluated the improvement in prognostic ability, in terms of survival C-statistics, passing from 
clinical to extended nested Cox models (i.e. clinical variables  +  miR-210-3p expression), among patients treated 
with EC + D. As shown in Table 2, although the nominal statistical significance was never reached for all tested 
models, slightly improvements were found in MFS at 3 and 5 years. Indeed, for MFS at 3 years, the clinical 
model achieved a survival C-statistic of 0.821 (95%CI: 0.707–0.935) and, with the further inclusion of miR-210 
as covariate, such C-statistic increased to 0.891 (95%CI: 0.801–0.981) (improvement p-value = 0.102) whereas 
for MFS at 5 years, the clinical model achieved a survival C-statistic of 0.760 (95%CI: 0.602–0.917) and, with 
the further inclusion of miR-210-3p, such C-statistic increased to 0.868 (95%CI: 0.751–0.984) (improvement 
p-value = 0.077). These findings further support the hypothesis that miR-210-3p expression may predict therapy 
response in patients treated with docetaxel in sequential therapy with epyrubicin and cyclofosfamide.
In silico prediction of miR-210-3p and docetaxel cross-talk. In the attempt to provide biological 
relevance to our results, we interrogated the DrugBank and miRWalk databases to retrieve the molecular targets 
Analysis
Time-to-event 
outcome Chemotherapy SD N. total N. events HR 95%CI p-value
Unadjusted
PFS
EC 111.596 43 10 1.33 0.96–1.85 0.085
EC + D 16.622 54 11 2.13 1.33–3.39 0.002
FEC 19.045 46 13 1.32 0.82–2.14 0.256
OS
EC 111.596 43 4 Not est. Not est. Not est.
EC + D 16.622 54 5 3.50 1.69–7.24 0.001
FEC 19.045 46 10 1.21 0.72–2.03 0.474
MFS
EC 111.596 42 8 0.69 0.15–3.28 0.644
EC + D 16.622 53 10 2.35 1.51–3.67 <0.001
FEC 19.045 46 15 1.12 0.70–1.80 0.627
Adjusted*
PFS
EC 111.596 39 10 1.34 0.94–1.91 0.105
EC + D 16.622 52 10 2.14 1.26–3.63 0.005
FEC 19.045 44 12 1.26 0.74–2.13 0.389
OS
EC 111.596 39 4 Not est. Not est. Not est.
EC + D 16.622 52 5 Not est. Not est. Not est.
FEC 19.045 44 9 1.16 0.68–1.98 0.579
MFS
EC 111.596 38 8 0.58 0.05–6.64 0.665
EC + D 16.622 51 10 2.48 1.47–4.19 0.001
FEC 19.045 44 13 1.01 0.64–1.61 0.957
Table 1. Association between miR-210-3p expression and time-to-event outcomes according to adjuvant 
chemotherapy schemes. Results are reported as hazard ratios (HRs), along with their 95% confidence 
interval (CI), which were expressed for each unitary increase in one standard deviation (SD) of miR-210-3p 
expression, as specifically detailed. Abbreviations: Not est = HR not estimated because of failing in model’s 
convergence; PFS = Progression Free Survival; OS = Overall Survival; MFS = Metastases Free Survival; 
EC = Epirubicin + Cyclofosfamide; EC + D = Epirubicin + Cyclofosfamide + Docetaxel; FEC = 5-Fluoro-
uracyl + Epirubicin + Cyclofosfamide). *Adjusted HR estimated from Cox models which included prognostic 
factor according to 2018 AJCC 8th classification Pathological Stage, Grade HER2/neu, Estrogen Receptor and 
Progesterone Receptor.
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of Docetaxel and miR-210-3p, respectively (Fig. 2A). Twelve out of twenty targets were in common between the 
two, thereby suggesting being committed to a common molecular program. In particular, common genes resulted 
to be associated with the Cancer drug response by drug efflux and PXR/RXR activation pathways, as well as to 
Breast cancer regulation by Stathmin 1, 14-3-3-mediated signalling and NRF2-mediated oxidative stress response 
pathways (Fig. 2B).
Discussion
To date, several studies have profiled the miR-210-3p expression in breast cancer patients and some of those have 
actually found significant correlations with the clinical outcome in support of the putative role that miR-210-3p 
might assume as biomarker in the management of BC patients6,10,17,18,24. In this context, due to the contradicting 
results we found in the literature, we took the effort to carry out the expression analysis of miR-210-3p in our 
cohort of 283 breast cancer patients followed by correlation analyses with the clinicopathological parameters to 
assess the capability to predict the clinical outcome of BC patients. As expected, miR-210-3p was significantly up 
regulated in tumours as compared with normal breast tissues. Moreover, consistently with previous findings, the 
Triple Negative BC molecular subgroup showed the highest levels of miR-210-3p expression, followed by Luminal 
B tumours, whereas Luminal A and HER2-amplified tumours showed the lowest expression levels.
Figure 1. Prognostic ability of miR-210-3p expression in predicting survival outcomes in patients treated with 
Epirubicin-Ciclofosfamide and Docetaxel regimen. AUC curves and Kaplan Meier analysis are shown for (A) 
Overall Survival (OS), (B) Progression Free Survival (PFS), and (C) Distant Metastases Free Survival (MFS).
Survival C-statistic (95%CI*)
Outcome# Time (years) N. total N. events Clinical model Clinical + miR210 model p-value°
PFS
3 52 7 0.769 (0.595-0.942) 0.860 (0.717–1.002) 0.250
5 52 8 0.748 (0.595–0.902) 0.825 (0.656–0.993) 0.409
10 52 10 0.741 (0.590–0.892) 0.757 (0.593–0.922) 0.805
MFS
3 52 8 0.821 (0.707–0.935) 0.891 (0.801–0.981) 0.102
5 52 9 0.760 (0.602–0.917) 0.868 (0.751–0.984) 0.077
10 51 10 0.764 (0.618–0.910) 0.821 (0.691–0.951) 0.318
Table 2. Improvement in prognostic ability from clinical Cox models (which included: pathological stage, 
grade, HER2/neu, estrogen receptor and progesterone receptor as clinical covariates) to extended Cox models, 
which included the covariates stated above and miR-210-3p expression, in patients treated with EC + D 
(N = 54). Abbreviations: PFS = Progression Free Survival; MFS = Metastasis Free Survival. *95% confidence 
interval derived following perturbation-resampling methods; °testing whether the prognostic ability achieved 
by the clinical model changed after the inclusion of miR-210-3p as prognostic covariate (i.e. two nested Cox 
models); #Overall Survival outcome was not considered because HRs miR-210-3p expression could not be 
estimated in the multivariable Cox models.
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Nevertheless, in agreement with a few reports21,22,25, the association of miR-210-3p with patient’ clinical out-
come (i.e. OS, PFS and MFS) in the subgroup of patients without synchronous metastases did not reach the 
statistical significance in any molecular subgroup. This lack of significant associations with clinical endpoints in 
the total population suggested us to explore the possibility that miR-210-3p might be associated with outcomes 
within patient subgroups stratified according to treatment because of its documented involvement in hypoxia 
and, thereby, multidrug resistance9,19,26–28. In fact, when we performed the subgroup analyses evaluating the asso-
ciation of miR-210-3p with the response to adjuvant chemotherapy, we did not find any significant association 
with FEC and EC schedules but we did find that higher levels of miR-210-3p were associated with a 2-fold risk 
of disease progression under EC + D regimen. Moreover, when we evaluated the ability of miR-210-3p analysis 
in this adjuvant setting to identify those patients who progressed or died for the disease, we could establish a cut 
off value of 20.966 able to predict with a high sensitivity and specificity the development of distant metastases 
and overall survival at short-term and long-term follow up, respectively. The addition of miR-210-3p expression 
together with the clinical parameters indicated by the 8th AJCC classification23 demonstrated a slight increase 
in survival C-statistic for the prediction of metastases free survival but without nominal statistical significance
Docetaxel is a second-generation taxane that, together with paclitaxel, belongs to the class of microtubule- 
stabilizing agents (MSAs) that bind to polymeric tubulin and prevent microtubule disassembly thus suppressing 
spindle microtubule dynamics, blocking mitosis and inducing apoptosis, and mitotic catastrophe following DNA 
damage. To uncover the molecular mechanisms underlying the role of miR-210-3p in resistance to Docetaxel 
we carried out a bioinformatic analysis that identified, among the targets of miR-210-3p and Docetaxel, twelve 
common molecules. (Fig. 2A) associated with microtubule regulation, drug efflux metabolism, and oxidative 
stress response (Fig. 2B). With regards to microtubule regulation, Docetaxel and miR-210-3p common targets 
participate to the 14-3-3 signaling that is involved in tubulin assembly29, and affects the function of Stathmin 1 
Figure 2. Identification of common molecules among miR-210-3p targets and Docetaxel interactors. 
(A) Molecular targets of miR-210-3p (red-linked) and Docetaxel (green). Circles are molecules which 
Docetaxel binds to, resulting in an alteration of the normal function of the bound molecule; Down-arrows are 
transporters; Rhombs are proteins which catalyze chemical reactions involving Docetaxel as substrate.  
(B) Known pathways which common molecules participate to.
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(STNM1), a protein that destabilizes microtubule polymers of α-tubulin and β-tubulin subunits30. Interestingly, 
several studies suggest that the polymerization state of microtubules can affect the binding of antimicrotubule 
drugs. Indeed, increased microtubule polymerization augmented the binding of paclitaxel to microtubule31,32. 
Accordingly, decreased microtubule polymerization associated with overexpression of STNM1 decreased the 
binding of paclitaxel to breast cancer cells33.
It is well established that drug metabolism pathways play a pivotal role in multidrug resistance and our 
bioinformatic analysis also identified the drug efflux pathway, the PXR/RXR activation signaling and the 
NRF2-mediated Oxidative Stress Response as putatively involved in the interaction between miR-210-3p and 
Docetaxel targets. In particular, miR-210-3p expression is regulated at transcriptional level by the hypoxia induc-
ible factor 1 alpha (HIF-1α) which directly binds to the hypoxia-responsive elements (HREs) at the MIR210 gene 
promoter34. Interestingly, a recent study found anti-oxidant response elements (ARE) in the HIF-1α promoter, 
supporting the hypothesis that NRF2 activation sustains cell survival during hypoxia and hypoxia/reoxygena-
tion35. Taken together, these data likely support a NRF2- HIF-1α-miR-210-3p axis as a further mechanism by 
which miR-210-3p might promote taxane resistance in cancer cells.
Although the analysis of treatment subgroups suffers from small sample size and, thus, low statistical power, to 
the best of our knowledge, this is the first study that brings into light a putative relationship between miR-210-3p 
and cancer responsiveness to taxanes in breast cancer and, hence, suggests the possibility to early predict the 
effectiveness of taxane-including schedules in patients undergoing adjuvant chemotherapy. The lack of previous 
evidences might be explained by taking into account that the subclassification and clinicopathological informa-
tion of retrospective BC cohorts, with a long-term follow up, might be biased by the regular update of the clinical 
practice guidelines as well as the implementation of new therapeutic options, such as the adjuvant chemotherapy 
based on anthracyclines (doxorubicin, daunomycin, and epirubicin) and taxanes (paclitaxel and docetaxel). In 
addition to this, the different, often limited, sample size of analyzed cohorts, variations in technical and analytical 
procedures might be all responsible of the inconsistencies among the reports and highlight the need for standard-
ization to make miRNA-based biomarkers of clinical utility.
Conclusions
Overall, our data support the association of miR-210-3p with docetaxel and, therefore, the hypothesis that detect-
ing the levels of miR-210-3p expression in the primary tumour may predict therapy response in patients treated 
with docetaxel in sequential therapy with anthracyclines. According to the ingenuity pathway analysis, hsa-miR-
210-3p may affect pathways involved in both docetaxel metabolisms as well as in its function in microtubule 
stabilization. Thus, the increased expression of miR-210-3p may indicate a taxane-resistant prone cancer cell state.
Materials and Methods
Design, setting and eligibility criteria. This study, aimed at evaluating the expression profile of hsa-
miR-210-3p in breast cancer, was carried out according to the REporting guidelines of tumor MARKer Studies 
(REMARK)36. A written research plan had been previously reviewed and approved by the Institutional Ethics 
Committee at IRCCS “Casa Sollievo della Sofferenza” (Prot N 140/CE). All the expression analyses were per-
formed in snap-frozen fresh tissue specimens from a prospectively collected cohort of 283 breast cancer patients, 
characterized by a median follow-up of 75.6 (IQR 41.6–109.6) months. The eligible participants were females, 
aged more than 18 years, subjected to surgery at the Breast-Unit, IRCCS “Casa Sollievo della Sofferenza”, in the 
period between May 2005 and December 2014. Due to legal reasons, only one tumor specimen (approximately 
50–100 mg of frozen tissue in weight) could be collected from each patient if the tumour was at least 1.0 cm in 
diameter. All patients provided prior written informed consent and all the procedures were performed according 
to International (Helsinki Declaration 7th rev, 2013, EU Directive 2004/23/EC) and Italian (D. Lgs. 30/06/2003, 
n. 196) regulations for research on human subjects.
Patients and treatment. The clinicopathological information of our patient cohort was collected from medical 
records and is presented in Supplemental Table S1. The median age of the study population is 59 years (range, 29 
to 82), median tumor size is 2.5 cm (range, 0.5 to 11.0). Synchronous metastases were present in 15 cases whereas, 
among non-metastatic patients (N = 268), 55 experienced disease progression (Incidence Rate, IR 3.555 events 
per 100 PY) and 29 of them (IR 1.729 events per 100 PY) died for the disease.
Data were presented in accordance with recommendations for tumour biomarker prognostic studies34: In 
particular, tumors were considered estrogen receptor- (ER-) or progesterone receptor- (PgR-) positive when ≥1% 
of immunoreactive cells was detected37. HER2 status assessment was carried out according to standard recom-
mendations38. Of the 283 patients, 106 (37%) were lymph node negative and 177 (63%) lymph node positive.
Due to the lack of reimbursement, multigene tests are currently not readily available for all patients in many 
countries including Italy. Consequently, the use of immunohistochemistry (IHC)-based biomarkers, such as 
Ki67, has been proposed in order to identify patients with low-risk outcome39. However, the 2015 St. Gallen panel 
proposed that Ki67 scores should be interpreted in light of local laboratory values, and recommended to use the 
median expression of each lab to define high and low values40,41. Thus, we used the median value in the study 
population, as cut off to distinguish low and high Ki67 expressing cases. According to this, Luminal A tumours 
were defined as HER2-negative, ER-positive, PgR positive with a low Ki67 assessment (<30%) and Luminal 
B-like tumours were defined as HER2-, ER-positive with a high Ki67 expression (≥30%). Overall, 103 cases 
(38%) were Luminal A, 94 cases (35%) were Luminal B; 33 HER2-amplified cases (12%), and 38 Triple Negative 
cases (14%). The remaining 15 cases were not classified because HER2 and/or Ki67 status was unknown. The 
patients of our cohort received adequate breast conserving surgery or total mastectomy and sentinel node biopsy 
or complete axillary dissection. Afterwards, the management of patients was performed as stated by to the follow-
ing guidelines: AIOM (Associazione Italiana Oncologia Medica), St Gallen, NCCN and ASCO. Progression was 
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defined as evidence of loco-regional (recurrence) and/or distant disease over 4 months from diagnosis and after 
curative-intent surgical treatment.
RNA isolation and RT-qPCR for miRNA detection. The RNAs extracted from 500 ng of fresh fro-
zen tissues were selected on the basis of RIN (RNA Integrity Number) calculation as previously described42. To 
assess miR-210-3p expression levels in our cohort of breast cancers we applied a relative quantification method 
(RT-qPCR) with standard curve (ref miR-9). Real-time PCR reactions were performed on ABI PRISM 7900HT 
Sequence Detection System (Thermo Fis Sc). For both miR-210-3p (ID 000512, Thermo Fisher Sc) and RNU48 
endogenous control (ID 001006, Thermo Fisher Sc), standard curves were constructed by plotting the threshold 
cycle (Ct) values against logarithm10 of the copy number and fitting by linear least square regression. The level of 
miR-210-3p expression in each sample was determined following the method described previously42.
Statistical analysis. Patients’ clinicopathological characteristics were reported as median along with inter-
quartile range (IQR, i.e. first-third quartiles) for continuous variables, and frequencies for categorical variables. 
The two-sample t-test (or ANOVA model as appropriate) was used to evaluate differences in miR-210-3p expres-
sion among patient groups. In case of ANOVA model, pairwise comparisons among groups were performed and 
p-values were adjusted following the Bonferroni correction.
Normal distribution assumption was evaluated by Q-Q plots and Shapiro-Wilks test. These analyses demon-
strated a log-normal distribution for miR-210-3p. Thus, all statistical analyses involving miR-210-3p expression 
were performed with their log transformed values.
Univariable and multivariable proportional hazards Cox regression models were used for time-to-event anal-
yses, and risks were reported as Hazard Ratios (HR) and their 95% Confidence Interval (95%CI). miR-210-3p 
expression levels were considered both as continuous variables (i.e. HRs were expressed for each unitary increase 
in one standard deviation of expression levels) and as categorized variables, with respect to its median.
The time between the enrollment date and cancer related death was defined Overall Survival (OS), whereas 
the time-intervals between the enrollment date and tumour progression or metastases development were defined 
Progression Free Survival (PFS) and Metastasis Free Survival (MFS), respectively. Furthermore, the rates of mor-
tality and disease progression were reported as number of events per 100 person-years.
The prognostic ability of miR-210-3p expression levels in discriminating patients who experienced a 
time-to-event outcome was assessed by the Area Under the Receiver Operating Characteristic (ROC) curves 
(AUC), censoring the follow-up time at different prediction time horizons (i.e. 3, 5 and 10 years), along with 
their 95% confidence intervals (95%CI), following DeLong method43. Moreover, the modified C-statistics for 
censored survival (i.e. “survival C-statistics”) data were estimated following Uno’s approach44 along with their 
95% CI (confidence interval estimated using the perturbation-resampling method). The optimal cut-off which 
jointly maximizes both sensitivity and specificity in the ROC space was detected and plotted along with the ROC 
curve. Patients were therefore classified into two groups: those with the miR-210-3p expression lower the detected 
cut-off and those with the miR-210-3p expression greater than or equal to the detected cut-off. Kaplan-Meier 
curves were also plotted with respect to these two patients’ groups and log-rank test was performed. Furthermore, 
in the subgroup of patients treated with Docetaxel, improvement in prognostic ability achieved from two nested 
proportional hazards Cox models, was assessed following the method proposed by Uno’s44, concerning the infer-
ence for the difference in survival C-statistics between two competing risk prediction models. In detail, the first 
Cox model included the following clinical covariates: staging, grading, HER2/neu, estrogen receptor and pro-
gesterone receptor as clinical covariates (also used to perform multivariable Cox models) whereas the second 
(nested) one further included the miR-210-3p expression. The SAS Release 9.4 (SAS Institute, Cary, NC, USA) 
software was used to perform all statistical analyses, whereas plots were generated by using Comprehensive R 
Archive Network (CRAN) version 3.5.1 (packages: pROC, survC1, survival). A p-value below 0.05 was considered 
for statistical significance.
Bioinformatic analyses. Molecular targets of miR-210-3p were retrieved from miRBase (version 3.0, 
accessed on October 2018). Among all targets, only experimentally verified targets were considered. DrugBank 
(version 5.1.1, accessed on October 2018) was queried in search of the molecular targets of Docetaxel. We divided 
the resulting targets into (i) proteins, macromolecules, nucleic acids, or small molecules to which Docetaxel binds, 
resulting in an alteration of the normal function of the bound molecule; (ii) enzymes that involve Docetaxel in 
their catalyzing functions; (iii) transporters that shuttle ions, small molecules or macromolecules across mem-
branes, into cells or out of cells.
Common targets between miR-210-3p and Docetaxel were submitted to Ingenuity Pathway Analysis software 
and annotated with the molecular pathways that were involved in.
Ethics approval and consent to participate. The experimental protocol was approved by the Ethical 
Committee of the Fondazione IRCCS “Casa Sollievo della Sofferenza” (Prot N140/CE). Prior written informed 
consent was obtained from all patients in accordance with the experimental protocol approved by the Ethical 
Committee.
Data availability
The datasets analysed during the current study are available from the corresponding author on reasonable request.
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